Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Business segments
Q2 2026 · $1.10BThe company’s own SEC segment disclosure.
- United States$893.5M81%
- Non Us$208.9M19%
Dexcom (DXCM) reported revenue of $1.31B in Q2 2026 (quarter ended June 30, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 63% and net income of $249M (19% of revenue). For the full year FY2025, revenue was $4.66B (+16% year on year) and net income $836M. Its largest region in 2026-Q2 was United States at $894M, 81% of the disclosed total, just ahead of Non Us at 19%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Devices
Ranks #12 of 35 by Smart Score